ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

Conditions

• COVID-19

Eligibility Criteria

Sex

ALL

Age

18 Years - 99 Years

Healthy Volunteers

Not accepted

Interventions

• Placebo — OTHER
  Risankizumab placebo will be given at an equal volume at the same schedule.
• Remdesivir — DRUG
  Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
• Risankizumab — BIOLOGICAL
  Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.

Study Details

This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19). Big Effect Trial (BET) is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 70 domestic sites and 5 international sites. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention. The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses. One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 200 (100 treatment and 100 shared placebo) subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once. The BET-A stage will evaluate the combination of remdesivir with risankizumab vs remdesivir with a risankizumab placebo. The primary objective is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.

Key Dates

Start date

Oct 23, 2020

Status verified

Sep 2021

Primary completion

Sep 13, 2021

Completion

Sep 13, 2021

Study Design

Enrollment

214 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Remdesivir + Placebo
  200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100.
• Experimental: Remdesivir + Risankizumab
  200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100.

Primary Outcome Measure

Number of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories on Day 8 [ Time Frame: Day 8 ]

Locations (32)

Find similar trials in Tucson, AZ

Related Studies

• Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
  PHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
• Positron Emission Tomography (PET) Imaging of Thrombosis
  PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
• Impact of the Coronavirus (COVID-19) on Patients With Cancer
  Recruiting · Stanford University · Stanford, California
• Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19
  Enrolling By Invitation · Duke University · Durham, North Carolina